|
Targeted therapy for gastrointestinaI (GI) tumors based on molecular profiles: Early results from MyPathway, an open-label phase IIa basket study in patients with advanced solid tumors. |
|
|
No Relationships to Disclose |
|
|
Research Funding - Genentech (Inst) |
|
|
Stock and Other Ownership Interests - Epic Sciences |
Honoraria - Boehringer Ingelheim; GlaxoSmithKline; Novartis |
Consulting or Advisory Role - Sarah Cannon Research Institute |
Research Funding - Boehringer Ingelheim |
|
|
No Relationships to Disclose |
|
|
Stock and Other Ownership Interests - BIND Biosciences; Leuchemix |
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; BIND Biosciences; Genentech/Roche; Janssen Biotech; Sanofi |
Research Funding - Astellas Pharma (Inst); Exelixis (Inst); Janssen Biotech (Inst) |
Patents, Royalties, Other Intellectual Property - Leuchemix, Parthenolide, Dimethylaminoparthenolide. Exelixis: Abiraterone plus cabozantinib combination |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Honoraria - Genentech; Roche; Sysmex |
Consulting or Advisory Role - Genentech; Inflection Biosciences; Novartis; Roche |
Research Funding - AstraZeneca; Bayer; Calithera Biosciences; Debiopharm Group; Genentech; Novartis; Taiho Pharmaceutical |
|
|
Employment - HCA Healthcare |
|
|
|
Stock and Other Ownership Interests - Genentech |
Research Funding - Genentech |
Travel, Accommodations, Expenses - Genentech |
|
|
Employment - Roche/Genentech |
Stock and Other Ownership Interests - Roche/Genentech |
|
|
Employment - Roche/Genentech |
Stock and Other Ownership Interests - Roche/Genentech |
|
|
Honoraria - Genentech; Novartis |
Consulting or Advisory Role - Genentech |